Abstract Aims/hypothesis: The aim of this study was to explore the contribution of genetic factors to the emergence of beta-cell-specific humoral autoimmunity. Subjects and methods: We analysed the effect of HLA class II, insulin (INS; −23 HphI variant) and cytotoxic T-lymphocyteassociated protein 4 (CTLA4 [+49 and CT60]) genes on the appearance of beta-cell-specific autoantibodies in a large population-based birth cohort recruited in Finland. Infants carrying increased risk HLA DQB1 genotypes were monitored for the appearance of autoantibodies (islet cell autoantibodies [ICA], insulin autoantibodies [IAA], glutamic acid decarboxylase autoantibodies [GADA] and islet antigen 2 antibodies ). Those who developed betacell-specific autoantibodies were studied (n=574, mean follow-up time: 4.9 years; range 0.5-9.3). Results: IAA emerged at a higher rate in children with the −23 HphI AA INS genotype than in those carrying AT or TT variants (hazard ratio 2.1, 95% CI 1.4-2.9, p<0.001). This effect of the INS locus was present in both HLA DQB1 risk groups. The appearance of IAA showed a strong association also with the HLA DRB1*0401 allele (hazard ratio 13.1, 95% CI 1.8-93.4, p<0.001). The development of IA-2A was also somewhat accelerated by the DRB1*0401 variant (p=0.03). Isolated ICA positivity was independent of the HLA and INS genotypes. None of the humoral immune markers showed association with the CTLA4 gene. Conclusions/interpretation: The INS and the DRB1 loci appear to contribute to the pathogenesis of type 1 diabetes by initiating/modifying insulin-specific autoimmunity. The emergence of IAA represents a crucial step in the development of beta cell autoimmunity in young children, in whom the appearance of GADA and IA-2A is linked to IAA.
Introduction
Type 1 diabetes develops in genetically susceptible individuals as a result of immune-mediated damage of the pancreatic beta cells. Although cellular immunity is perceived to play a central role in the effector phase of islet destruction, a combination of humoral markers (islet cell autoantibodies [ICA] , insulin autoantibodies [IAA] , glutamic acid decarboxylase autoantibodies [GADA] and islet antigen 2 antibodies [IA-2A]) has proved to be a useful tool for monitoring the development of islet autoimmunity and for prediction of progression to clinical disease [1] [2] [3] [4] . Although the association of certain HLA haplotypes with the appearance of IAA, GADA and IA-2A seems to be consistent in various studies [5] [6] [7] [8] , it is still unclear at what stage of the autoimmune process the HLA genes exert their effect.
Although the HLA gene region accounts for approximately half of the genetic disease susceptibility, a number of other 'minor' loci also contribute [9] [10] [11] . The insulin gene (INS; IDDM2) and the cytotoxic T-lymphocyteassociated protein 4 (CTLA4) gene regions (IDDM12) are considered as confirmed non-HLA disease susceptibility loci [12] [13] [14] [15] [16] . Short (class I) alleles of the insulin gene 5′ variable number of tandem repeats (VNTR) are associated with increased type 1 diabetes susceptibility fitting an allele dosage model, while long class III alleles confer protection [17] . In the CTLA4 region, a number of variants, like the +49A/G, have shown disease association in various ethnic groups, while the CT60 polymorphism was identified as a candidate causative disease variant [14] [15] [16] 18] .
Our knowledge of the effect of the insulin and CTLA4 gene regions on type 1 diabetes-associated humoral autoimmunity is limited and controversial. An early study observed no association between the INS VNTR genotype and insulin-specific cellular and humoral autoimmunity [19] , while class I alleles of the VNTR were found to contribute to the emergence of IAA in a larger case-control comparison [7] . It has also been suggested that the INS locus confers increased disease risk only in subjects with moderate-risk HLA genotypes [20] . However, recent studies have suggested that the INS polymorphism could modify progression to clinical disease among individuals with both high-risk and low-risk HLA genotypes [21] [22] [23] . Data on the effect of the CTLA4 gene region on beta cell autoimmunity are similarly ambiguous. The CTLA4-3′(AT)n microsatellite and the +49A/G polymorphism showed no association with humoral autoimmunity in Swedish and Belgian cohorts, whereas IA-2A showed association with the G allele of the +49A/G polymorphism in a Japanese study [7, 24, 25] .
In the Type I Diabetes Prediction and Prevention project (DIPP) currently underway in Finland, population-based genetic screening for type 1 diabetes-associated HLA DQB1 genotypes is performed in newborn infants followed by continuous monitoring of beta-cell-specific humoral autoimmunity in the risk cohort [26] . The aim of this study was to analyse the effect of the HLA class II, INS-VNTR and CTLA4 loci on the development of diabetes-associated autoantibodies in an early phase of the autoimmune process.
Subjects and methods

Study design
In the framework of the DIPP study, screening for HLAconferred susceptibility to type 1 diabetes is performed in all infants born in three university hospitals in Finland, i.e. Turku, Tampere and Oulu [26] . All infants (n>9,000 by May 2004) with risk HLA DQB1 genotypes (DQB1*02/ *0302, DQB1*0302/X, DQA1*05-DQB1*02/Y, where x≠DQB1*02, DQB1*0301, DQB1*0602, y≠DQA1*0201-DQB1*02, DQB1*0301, *0302, *0602 or *0603) were followed and sampled at 3-12-month intervals as described [26] . ICA were measured in all serum samples and, if positive, IAA, GADA and IA-2A were tested in all serum samples available from that ICA-positive subject. In this study, we analysed HLA class II, INS and CTLA4 genotypes in relation to humoral islet autoimmunity. The local ethics committees had approved the study and informed consent was obtained from the parents of the participating subjects. All study subjects were of Finnish ethnic origin. The study was conducted according to the principles of the Declaration of Helsinki.
Study population
Antibody-positive children All children who had developed ICA by May 2004 (n=574, 180 with the DQB1*02/ DQB1*0302 high-risk, 368 with the DQB1*0302/X and 26 with the DQA1*05-DQB1*02/Y moderate-risk genotypes, 53.5% boys) were tested for autoantibodies (IAA, GADA and IA-2A) and for genetic markers (HLA DRB1-DQA1-DQB1, INS −23 HphI as well as CTLA4+49 and CT60 polymorphisms). At the time of this analysis the mean (±SD) follow-up time in the DQB1*02/DQB1*0302 and DQB1*0302/X groups was 4.9±2.2 years (range 0.5-9.3 years), while it was somewhat shorter in those carrying the DQB1*02/y combinations (mean 3.9±1.4 years, range 0.5-6.1 years). By May 2004, 74 of these children (12.9%) had progressed to clinical type 1 diabetes diagnosed according to the WHO criteria.
Healthy control children without antibodies The control group comprised ICA-negative healthy children, who were randomly selected, but matched for sex, age and place of birth, from the entire DIPP birth cohort (n=2,563, 52.9% boys, mean age 3.6±1.5 years). HLA DQB1 typing was done in all controls according to the DIPP screening scheme [26] . DQA1 typing was performed in individuals with DQB1*02, while DQB1*0302-positive children were DRB1*04 subtyped. The INS and CTLA4 gene polymorphisms were typed as described below. This group was used for comparisons in the analysis of genetic effects on the appearance of ICA.
Methods
Genotyping The methods and the resolutions for the HLA DQB1 'full house' for the DQA1 and DRB1*04 typing were described earlier [27] [28] [29] . The INS −23 HphI and the CTLA4+49 polymorphisms were analysed using PCR and a lanthanide-labelled oligonucleotide hybridisation method [27, 30] . (CTLA4+49 A probe: 5′-Terbium-TGGCTAC-CAGGA-3′; G probe: 5′-Terbium-GGCTGCCAGGA-3′; −23 HphI T probe: 5′-Europium-CTGTCTCCCAGA-3′; A probe: 5′-Terbium-CTGTCACCCAGA-3′). CT60 was genotyped using minisequencing (SnuPe Kit; GE Healthcare-formerly Amersham Biosciences-Chalfont St Giles, UK) and a MegaBACE 1000 sequencer (GE Healthcare).
Autoantibody assays The antibody assay parameters that apply have been described in detail [4] . The detection limit for ICA was 2.5 JDFU (sensitivity 100%, specificity 98%). IAA titres were quantified with a microassay [31, 32] . GADA and IA-2A were measured using specific radioligand assays [33, 34] Statistical analysis Kaplan-Meier survival analysis was applied to evaluate genetic effects on the appearance of various autoantibodies. Differences between the survival curves were tested with log-rank test. Cox regression was employed to dissect the effect of various factors (antibody status, genotypes) on autoantibody-free survival. Longitudinal data of all antibody measurements that were available for the cohort of antibody-positive children were analysed using a linear mixed model where age and group were used as fixed factors and subject as a random factor to account for correlation between repeated measurements. Logarithmic transformation of the antibody titres was applied to normalise their distribution. In the comparison of HLA, INS and CTLA4 genotype frequencies between ICApositive children and ICA-negative controls, chi-square statistics with Yates' correction were used. To compare the highest autoantibody titres detected during the whole follow-up period in children carrying different genotypes, the Kruskal-Wallis and the Mann-Whitney U-tests were used. In multiple comparisons, Bonferroni corrections were used (shown as p c ); p values lower than 0.05 were considered statistically significant. All statistical analyses were done using SPSS for Windows (version 11.0.1; SPSS, Chicago, IL, USA).
Results
HLA DRB1-DQA1-DQB1 and the appearance of autoantibodies
The results of the Kaplan-Meier survival analysis on the emergence of autoantibodies in the various DQB1 genotype groups are shown in Table 1 . The median values for the antibody-free survival could not be calculated in most cases, since the cumulative antibody frequencies were usu- To explore the effect of DRB1*04 subtypes on the emergence of ICA, we compared the DRB1*04 allele frequencies in children who tested positive for ICA alone with those observed among the antibody-negative controls. There was no difference between the two groups (children testing positive for ICA only: DRB1*0401 57.9%, *0404 33.7%, *0403 6.7% vs controls 59.0, 32.8 and 7.2%, respectively).
The insulin locus and the appearance of autoantibodies Survival analysis of the effect of the insulin locus on the appearance of autoantibodies The cumulative frequency of IAA was higher and autoantibody-free survival was shorter in children with the INS −23 HphI AA genotype than in those carrying the AT or TT combinations (hazard ratio 2.1. [95% CI: 1.4-2.9] p<0.0001; Table 2 , Fig. 1a) . The effect of the INS locus on the development of IAA seemed even stronger in those children where IAA appeared as the first antibody (hazard ratio: 2.5 [95% CI 1.6-3.4] p<0.00001). Similarly, the cumulative frequency of IAA was increased also in −23 HphI AA carrying subjects who tested negative for GADA or IA-2A (Table 2 , Fig. 1b) . Accordingly, in the Cox regression model the effect of INS was significant after adjusting for the GADA and IA-2A carrier status (adjusted hazard ratio for the appearance of IAA in the −23HphI AA group was 1.7 [95% CI 1.2-2.4] reference: AT/TT genotype, p=0.004). The insulin locus had a clear effect on the development of IAA in all three DQB1 genotype groups (Fig. 1c, Table 3 ). In the Cox regression the effect of −23HphI on IAA development adjusted for HLA DQB1 effects was highly significant (hazard ratio for the AA combination 2.1 [95% CI 1.5-3.0], p<0.0001).
Similarly, the effect of the INS locus on development of IAA was present both in the DRB1*0401 and *0404 subtype categories (Table 3 ) (hazard ratio for the −23 HphI AA genotype adjusted for the DRB1*04: 2.0 [95% CI 1.4-2.9], p<0.0001). Cumulative frequencies of GADA and antibody-free survival showed differences between the INS −23 HphI AA and AT/TT genotype groups in the Kaplan-Meier analysis when the autoantibody data set was analysed unstratified (AA group 46.0% vs AT/TT group 31.8%, and 6.4 years [95% CI 6.1-6.8] vs 7.3 years [95% CI 6.7-7.8], respectively, log-rank 5.5, p=0.02; Fig. 2a) . However, no effect of the INS polymorphism was detected on the appearance of GADA when children were stratified according to their IAA status ( Table 2 , Fig. 2b ). Importantly, GADA appearance was strongly influenced by IAA status, as IAA-positive children developed GADA at a higher rate than IAA-negative children (hazard ratio 12.5 [95% CI 8.6-18.1], p<0.0001).
Similarly, in the unstratified data set the emergence of IA-2A appeared to be influenced by the −23 HphI variant (cumulative frequency in the AA group: 43.6 vs 35.9% in the AT/TT group; median antibody-free survival: 6.7 years [95% CI 6.3-7.1] vs 7.7 years [95% CI 7.2-8.1], respectively; log-rank 9.8, p=0.002; Fig. 2c) . However, no effect of the INS locus was observed when the cohort was stratified according to the IAA status (Table 2, Fig. 2d ). Emer- Fig. 3a) . Similarly, IAA titres were observed to be higher in both HLA categories in children with the −23 HphI AA genotype compared with those who had AT or TT (DQB1*02/ *0302-HphI AA 20. The CTLA4 gene polymorphisms and the appearance of autoantibodies No effect of the CTLA4+49 or CT60 polymorphisms on the emergence of islet-specific autoantibodies was observed in this study (data not shown).
Discussion
We analysed the effect of the insulin, the CTLA4 and the HLA DRB1-DQA1-DQB1 genes on the development of humoral beta cell autoimmunity in a large populationderived Finnish birth cohort with increased HLA DQB1-conferred genetic risk for type 1 diabetes (the DIPP study) [26] . The selection criteria for the study cohort comprising ICA-positive children limited our possibilities to analyse thoroughly the HLA effects, since most study subjects carried the DR4-DQB1*0302 haplotype, however, the contribution of the insulin and CTLA4 loci to the diseasespecific autoimmune phenomena could be fully explored. We also analysed the effect of DRB1*04 alleles on the DR4-DQB1*0302 haplotypes, since they confer different degrees of disease susceptibility in the Finnish population, as the DRB1*0401 allele is associated with higher risk than the DRB1*0404 variant and the DRB1*0403 allele is protective [28, 35] . At the INS locus the −23 HphI polymorphism was used as genetic risk marker, where the A alleles are in strong linkage disequilibrium with the 5′ INS VNTR class I susceptibility variants and the T alleles are linked with the protective class III alleles [12, 21] . The wellcharacterised CTLA4+49 and CT60 polymorphisms were chosen as disease markers at the IDDM12 locus [14, 16] . This is the first population-based study demonstrating that the INS locus affects the emergence of humoral beta cell autoimmunity and it provides strong evidence that INS directly influences humoral insulin-specific autoimmunity. A number of findings support this observation. Firstly, IAA emerged at a higher rate in children carrying the −23HphI AA genotype compared with those who had AT or TT variants. This effect appeared to be even more pronounced in those infants who developed IAA as their first antibody reactivity. These observations strongly support the importance of the INS locus in the initiation of the autoimmune process. Secondly, a gene dosage effect of the INS locus on the appearance of IAA was detected, as the autoantibody titre was proportional to the number of INS susceptibility alleles. Importantly, the INS locus influenced the development of IAA in all three HLA risk groups. Although the INS locus is associated with disease risk, the effect of INS on the emergence of IAA seems to be a genuine one, since IAA as such are not associated with particularly high diabetes risk [1, 4, 36] .
The association of IAA with the risk INS genotype is supported by observations made in two other recent studies on patients with newly diagnosed type 1 diabetes and on first-degree relatives [7, 22] . Recently, a more preserved beta cell function in recent-onset cases was found in individuals with the INS VNTR class III allele compared with those carrying class I alleles [37] . These data are in line with the hypothesis proposing that the INS-VNTR has a role in the regulation of insulin gene transcription in the thymus and modulation of insulin-specific self tolerance [38, 39] .
A positive association between IA-2A and GADA with the INS risk genotype was also implicated by the analysis of the unstratified data set; however, it is explained by the fact that the majority (81.7%) of IA-2A and GADApositive children also had IAA. The lack of a primary association between IA-2A or GADA and INS was clearly shown by the Cox regression and also by the survival analysis in the data set stratified according to the IAA status (see Fig. 2 ). These data points to the existence of two different pathways that result in the emergence of GADA and IA-2A. In the 'INS-dependent' pathway, insulin autoimmunity plays a central role in the initiation of the disease process, while the appearance of GADA and IA-2A is linked to the presence of IAA, probably by antigen spreading. In IAA-negative individuals the initiation of In the analysis on the relation of HLA class II and betacell-specific autoantibodies, the association of IAA and IA-2A with the DR4-DQB1*0302 haplotype was supported by our data as both antibodies developed at a higher rate in children carrying this haplotype compared with the DQA1*05-DQB1*02/Y group. In addition, children carrying the high-risk DQB1*02/*0302 genotype had higher positive seroconversion rates for these antibodies than those with the DQB1*0302/X combination. In the DQA1* 05-DQB1*02/Y group, GADA were the most frequent autoantibody reactivity detected. These observations are in line with findings by ourselves and other groups that indicate that the two major disease-associated HLA class II haplotypes could mediate alternative, although probably related pathways in the emergence of beta-cell-specific autoimmunity [5] [6] [7] [8] .
Importantly, we detected a differential effect of DRB1* 04 alleles present on the DR4-DQB1*0302 haplotypes on the development of diabetes-related autoantibodies, where the DRB1*0401 allele showed a considerably stronger effect on the emergence of IAA than the DRB1*0404 variant, while the DRB1*0403 allele almost completely blocked the appearance of antibodies. The absence of antibody response in children with DRB1*0403 could be related to the peptide binding specificity of the encoded DR molecule that has been shown to share three-dimensional and electro-chemical properties with particular HLA-DQ heterodimers protective from type 1 diabetes [40] . In the Cox regression analysis, no effect of the DRB1*04 subtypes was seen on the emergence of GADA, and the association of IA-2A with DRB1*0401 was only marginally significant. We also showed here that the effect of the INS locus is independent of the DRB1*04 variant. There are only limited published data on this issue. A previous Swedish study suggested that IA-2A were associated with DRB1* 0401 [41] , but otherwise possible links between the autoantibodies and the DRB1*04 alleles have remained unexplored. Our data indicate that the DRB1*0401 variant -which confers the highest disease risk in the Finnish population [35] -could play an important role in the initiation of the insulin-specific immune processes. In IAApositive subjects the development of GADA and IA-2A appear to be linked to IAA, therefore, this genetic variant could indirectly influence GAD and IA-2-related autoimmunity.
In the analysis of genetic effects on the appearance of ICA, survival analysis was not feasible to explore the contribution of DRB1*04 haplotypes as those data were not available for the whole follow-up cohort (>9,000 children). Therefore we compared frequencies of these haplotypes between children testing positive for ICA only (most of whom had ICA titres below 20 JDFU) and autoantibodynegative control children. No difference was seen in these comparisons. This and others' findings indicate that low ICA titres show no association with HLA, whereas children with multiple autoantibodies or high titres of ICA show a HLA genotype distribution resembling that seen in patients with type 1 diabetes [42] [43] [44] [45] . This implies that the appearance of low-titre ICA alone may represent harmless immune phenomena unrelated to the diabetes-specific disease process. It is important to note, that HLA seem to influence the progression of the autoimmune process, as the protective DQB1*0602 allele prevents development of diabetes in ICA-positive subjects [46, 47] .
In this study we could not see any effect of the CTLA4+ 49 and CT60 polymorphisms on type 1 diabetes-specific humoral autoimmunity. The findings were similarly negative in the Belgian and Swedish surveys, where the CTLA4 3′ UTR (AT)n microsatellite was used as genetic marker [7, 24] . However, IA-2A and CTLA4+49 A/G were reported to be associated with type 1 diabetes in Japanese patients, but this observation might be secondary to the increased prevalence of autoimmune thyroid disease among the patients included in that study [25] . Our findings indicate that the two polymorphisms in the CTLA4 region studied have no major role in type 1 diabetes-related humoral autoimmunity, the statistical power of the analysis being more than 90% to detect a hazard ratio of 1.6; α=0.05. It has to be noted, that the effect of CTLA4 on type 1 diabetes susceptibility is very weak in the Finnish population (OR<1.3 for the +49GG genotype; unpublished) and in that range the study had limited statistical power.
In conclusion, we propose that the insulin locus plays a central role in the initiation of the autoimmune process in IAA-positive individuals, while the appearance of GADA and IA-2A is a secondary phenomenon. In addition, the HLA DRB1*0401 variant also seems to have a role in the regulation of insulin autoimmunity. In IAA-negative individuals the development of GADA and IA-2A and progression to clinical disease is likely controlled by factors other than the INS locus.
